<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CO-CARELDOPA</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CO-CARELDOPA</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#effectOnLaboratoryTests" data-toggle="tab">Effect on laboratory tests</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Parkinson's disease</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 25/100 mg 3 times a day, then increased in steps of 12.5/50 mg once daily or on alternate days, adjusted according to response, alternatively increased in steps of 25/100 mg once daily or on alternate days, adjusted according to response, dose increased until 800 mg levodopa (with 200 mg carbidopa) daily in divided doses is reached, then maintenance up to 200/2000 mg daily in divided doses, adjusted according to response, when co-careldopa is used, the total daily dose of carbidopa should be at least 70 mg. A lower dose may not achieve full inhibition of extracerebral dopa-decarboxylase, with a resultant increase in side-effects.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Parkinson's disease&#8212;alternative regimen</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 12.5/50 mg 3&#8211;4 times a day, alternatively initially 10/100 mg 3&#8211;4 times a day, then increased in steps of 12.5/50 mg once daily or on alternate days, adjusted according to response, alternatively increased in steps of 10/100 mg once daily or on alternate days, adjusted according to response, dose increased until 800 mg levodopa (with up to 200 mg carbidopa) daily in divided doses is reached, then maintenance up to 200/2000 mg daily in divided doses, adjusted according to response, when co-careldopa is used, the total daily dose of carbidopa should be at least 70 mg. A lower dose may not achieve full inhibition of extracerebral dopa-decarboxylase, with a resultant increase in side-effects.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>The proportions are expressed in the form x/y where x and y are the strengths in milligrams of carbidopa and levodopa respectively.</p>
            </section>
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Use with caution&#8212;toxicity has occurred in <i>animal</i> studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Use with caution.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Use with caution.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abnormal dreams, anorexia, anxiety, arrhythmias, chorea, confusion, dementia, depression, dizziness, drowsiness, dry mouth, dyskinesia, dystonia, euphoria, fatigue, insomnia, nausea, palpitations, postural hypotension, psychosis, syncope, taste disturbances, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Ataxia, chest pain, constipation, diarrhoea, dysphagia, flatulence, hand tremor, hoarseness, hypersalivation, hypertension, malaise, muscle cramps, oedema, reddish discoloration of the urine and other body fluids, weakness, weight changes,
              </p>
              <p>
                <strong>rare:</strong> Abdominal pain, activation of Horner's syndrome, activation of malignant melanoma, agitation, agranulocytosis, alopecia, blepharospasm, blurred vision, bruxism, convulsions, diplopia, disorientation, duodenal ulcer, dyspepsia, dyspnoea, exanthema, flushing, gastro-intestinal bleeding, haemolytic anaemia, headache, Henoch-Sch&#246;nlein purpura, hiccups, leucopenia, neuroleptic malignant syndrome (associated with abrupt withdrawal), non-haemolytic anaemia, oculogyric crisis, paraesthesia, phlebitis, priapism, pupil dilatation, reduced mental acuity, sweating, thrombocytopenia, trismus, urinary incontinence, urinary retention,
              </p>
              <p>
                <strong>veryRare:</strong> Angle-closure glaucoma, suicidal ideation,
              </p>
              <p>
                <strong>notKnown:</strong> Compulsive behaviour,
              </p>
        
        
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Impulse control disorders</h3>
              <p>Treatment with levodopa is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. If the patient develops an impulse control disorder, levodopa should be withdrawn or the dose reduced until the symptoms resolve.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cushing's syndrome
          </li>
          <li>
            diabetes mellitus
          </li>
          <li>
            endocrine disorders
          </li>
          <li>
            history of convulsions
          </li>
          <li>
            history of myocardial infarction with residual arrhythmia
          </li>
          <li>
            history of peptic ulcer
          </li>
          <li>
            hyperthyroidism
          </li>
          <li>
            osteomalacia
          </li>
          <li>
            phaeochromocytoma
          </li>
          <li>
            psychiatric illness (avoid if severe and discontinue if deterioration)
          </li>
          <li>
            severe cardiovascular disease
          </li>
          <li>
            severe pulmonary disease
          </li>
          <li>
            susceptibility to angle-closure glaucoma
          </li>
        </ul>
      </section>




      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Co-careldopa is a mixture of carbidopa and levodopa; the proportions are expressed in the form x/y where x and y are the strengths in milligrams of carbidopa and levodopa respectively.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <p>When transferring patients from another levodopa/dopa-decarboxylase inhibitor preparation, the previous preparation should be discontinued at least 12 hours before.</p><p>Co-careldopa 25/100 provides an adequate dose of carbidopa when low doses of levodopa are needed.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <p>2 tablets <i>Sinemet</i>
            <tm tmtype="reg"/> 12.5&#8239;mg/50&#8239;mg &#8801; 1 tablet <i>Sinemet</i>
            <tm tmtype="reg"/> Plus 25&#8239;mg/100&#8239;mg.</p>
            </section>
      </section>

      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>Avoid abrupt withdrawal (risk of neuroleptic malignant syndrome and rhabdomyolysis).</p>
            </section>
      </section>




      <section class="tab-pane" id="effectOnLaboratoryTests">
        <h2>Effect on laboratory tests</h2>

            <section class="effectOnLaboratoryTests">
              <p>False positive tests for urinary ketones have been reported.</p>
            </section>
      </section>




      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CO-CARELDOPA</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,

            <div id="PHP77004"><a href="../medicinalForm/PHP77004.html" data-target="#PHP77004" data-action="load">Tablet</a></div>
            <div id="PHP77011"><a href="../medicinalForm/PHP77011.html" data-target="#PHP77011" data-action="load">Modified-release tablet</a></div>
            <div id="PHP77018"><a href="../medicinalForm/PHP77018.html" data-target="#PHP77018" data-action="load">Gel</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
